All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Andrés FerreriDuring ASCO 2019 held in Chicago, US, Andres J. Ferreri, San Raffaele Hospital, Milan, IT, spoke to the Lymphoma Hub about the overall strategies for primary central nervous system (CNS) lymphoma.
Andres J. Ferrari discusses the optimal induction strategy of high-dose methotrexate with an alkylating agent and rituximab, though he notes that in patients who are unable to receive chemotherapy, primary radiation can be considered. He moves on to discuss the multiple consolidation strategies that are available including; observation, whole-brain radiotherapy, high-dose chemotherapy + autologous stem cell transplant, non-myeloablative chemotherapy, or new oral drugs. He summarizes two main challenges; treating chemo-refractory disease (some new phase II trials concluded lenalidomide and ibrutinib can be used in this setting) and the low penetration of blood-brain barrier (recent reports suggest that using an engineered tumor necrosis factor can increase this penetration).
Overall strategies for primary CNS lymphoma
Your opinion matters
Which of the following do you consider a key challenge when implementing the BrECADD regimen for the treatment of Hodgkin lymphoma?